Joyce Noelly Vitor Santos

Ms. Joyce Noelly Vitor Santos

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2022 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
HAHellen Cristina Almeida
Hellen Cristina Almeida
VLVanessa Kelly da Silva Lage
Vanessa Kelly da Silva Lage
FPFabiana Angélica de Paula
Fabiana Angélica de Paula
JFJaqueline de Paula Chaves Freitas
Jaqueline de Paula Chaves Freitas
LMLauane Gomes Moreno
Lauane Gomes Moreno
VMVanessa Mendonça
Vanessa Mendonça
Ultra-processed foods (UP) are frequently associated with poor diet quality and lack many nutrients necessary for skeletal muscle health, which could contribute to developing sarcopenia. However, investigations about possible associations between the intake of UP and sarcopenia are missing. This study aimed to describe the magnitude of the exposition to UP (eating frequency) and compare it in older adults with and without sarcopenia. It also described associations between the magnitude of exposition of UP with body composition markers of sarcopenia in all subjects. It was a cross-sectional study with a sample of 118 community-dwelling older adults. Body composition was accessed by Dual-energy X-ray absorptiometry (DXA) and UP intake by a food frequency questionnaire (FFQ). All foods in the FFQ were categorized into two groups: (1) non-UP and (2) UP. SCORE I (mean score for food group 1) and SCORE II (mean score for food group 2) were calculated. The eating frequency of UP was near 3 to 4x/week and higher for sarcopenic subjects (p<0.05). Subjects consuming UP more than 1-2x/week were more likely to be sarcopenic than those consuming less than 1-2x/week. Therefore, sarcopenic subjects were more exposed to UP. In addition, even at a low exposition, the intake of UP increases the chances of developing sarcopenia in older adults.

FPFabiana Angélica de Paula
Fabiana Angélica de Paula
VMVanessa Mendonça
Vanessa Mendonça
VLVanessa Kelly da Silva Lage
Vanessa Kelly da Silva Lage
GSGuilherme Pinto da Silva
Guilherme Pinto da Silva
HAHellen Cristina Almeida
Hellen Cristina Almeida
Redha TaiarRedha Taiar
Redha Taiar
Whole-body vibration (WBV) exercises have recently been introduced as a nonpharmacological therapeutic strategy for sarcopenic older people. The present study aimed to evaluate the effect of WBV exercise on hemodynamic parameters in sarcopenic older people. Forty older people, divided into groups of nonsarcopenic (NSG = 20) and sarcopenic (SG = 20), participated in the study and were cross randomized into two interventions of eight sets of 40 s each, these being squatting with WBV and squatting without WBV. Heart rate (HR), peak heart rate (peak HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), double product (DP), mean arterial pressure (MAP), and subjective perception of effort (SPE), were assessed at baseline, during, and after a single WBV session. The HR, peak HR, and DP variables were similar at baseline between groups. WBV exercise increased all the hemodynamic parameters both during and immediately after the intervention, in both groups (SG and NSG). The MAP values were similar at baseline between groups; however, in the NSG there was a significant increase during and immediately after the squatting with WBV intervention (p < 0.05). The HR behavior, in both groups, showed that there was an increase in HR after the first set of exercises with vibration and this increase was maintained until the final set. The absence of adverse effects of WBV exercise on the cardiovascular system and fatigue suggests this exercise modality is adequate and safe for sarcopenic older people.

JSJoyce Noelly Vitor Santos
Joyce Noelly Vitor Santos
VMVanessa Mendonça
Vanessa Mendonça
AFAmanda Cristina Fernandes
Amanda Cristina Fernandes
LMLaísa Braga Maia
Laísa Braga Maia
NHNicholas Henschke
Nicholas Henschke
Redha TaiarRedha Taiar
Redha Taiar
Introduction: COVID-19 is a public health emergency all around the world. Severe illness occurred in about 14% of patients and 5% of patients developed critical illness, but the prognosis for these patients remains unclear. Objective: To describe the prognosis in hospitalized adults with COVID-19. Methods: The MEDLINE, EMBASE, AMED, and COCHRANE databases were searched for studies published up to 28 June 2021 without language restrictions. Descriptors were related to “COVID-19” and “prognosis”. Prospective inception cohort studies that assessed morbidity, mortality and recovery in hospitalized people over 18 years old with COVID-19 were included. Two independent reviewers selected eligible studies and extracted the available data. Acute respiratory distress syndrome (ARDS) and multiple organ failure (MOFS) were considered as outcomes for morbidity and discharge was considered for recovery. The Quality in Prognosis Studies (QUIPS) tool was used to assess risk of bias. Analyses were performed using Comprehensive Meta-Analysis (version 2.2.064). Results: We included 30 inception cohort studies investigating 13,717 people hospitalized with COVID-19 from different countries. The mean (SD) age was 60.90 (21.87) years, and there was high proportion of males (76.19%) and people with comorbidities (e.g., 49.44% with hypertension and 29.75% with diabetes). Findings suggested a high occurrence of morbidity, mainly related to ARDS. Morbidity rates varied across studies from 19% to 36% in hospital wards, and from 13% to 90% in Intensive Care Units—ICU. Mortality rates ranged from 4% to 38% in hospital wards and from 8% to 51% in ICU. Recovery rates ranged up to 94% and 65% in hospital wards and ICU, respectively. The included studies had high risk of bias in the confounding domain. Conclusions: The prognosis of people hospitalized with COVID-19 is an issue for the public health system worldwide, with high morbidity and mortality rates, mainly in ICU and for patients with comorbidities. Its prognosis emphasizes the need for appropriate prevention and management strategies.

14 July 2024 in Journal of Bodywork and Movement Therapies
Verified
Journal Article
Closed access
LOLais Santos de Oliveira
Lais Santos de Oliveira
MMMariana Aguiar de Matos
Mariana Aguiar de Matos
VLVanessa Kelly da Silva Lage
Vanessa Kelly da Silva Lage
ASAna Júlia Mendes de Sá
Ana Júlia Mendes de Sá
RBRenato Muniz Borba
Renato Muniz Borba
VMVanessa Mendonça
Vanessa Mendonça

3 November 2025 in Journal of Bodywork and Movement Therapies
Verified
Journal Article
Closed access
VRVanessa Gomes Brandão Rodrigues
Vanessa Gomes Brandão Rodrigues
JSJoyce Noelly Vitor Santos
Joyce Noelly Vitor Santos
VLVanessa Kelly da Silva Lage
Vanessa Kelly da Silva Lage
IMInara Caroline Marcelino Martins
Inara Caroline Marcelino Martins
EMElisângela Andrade Assis Madeira
Elisângela Andrade Assis Madeira
VMVanessa Mendonça
Vanessa Mendonça

1 January 2025 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
FAF.C. Araújo
F.C. Araújo
AAA.C.D. Amaral
A.C.D. Amaral
HSH.J. Silva
H.J. Silva
JSJoyce Noelly Vitor Santos
Joyce Noelly Vitor Santos
VMVanessa Mendonça
Vanessa Mendonça
EREtel Rocha-Vieira
Etel Rocha-Vieira
This systematic review of inception prospective cohort studies aimed to investigate whether autoantibodies are potential prognostic factors for short- and long-term clinical outcomes of COVID-19. Searches were conducted in MEDLINE, EMBASE, AMED, GLOBAL HEALTH, and COCHRANE databases from 2019 to 2022. When possible, meta-analysis was conducted, otherwise findings from individual studies were reported using odds ratios (OR) with 95% confidence intervals (CI). Quality of evidence was summarized using the GRADE criteria. We identified 2292 references, 18 inception prospective cohort studies (3178 patients) were included in the systematic review, and 12 studies reached criteria for meta-analysis. Studies achieved, in general, low to moderate risk of bias. Moderate quality of evidence showed that anti-interferon (IFN) was associated with increased risk of severity (OR=7.75; CI=1.79-33.61) and mechanical ventilation (OR=4.19; CI=2.06-8.53), but not with COVID-19 mortality (OR=1.68; CI=0.63-4.44). Antiphospholipids were not associated with COVID-19 mortality (OR=1.42; CI=0.85-2.37; P=0.18; I2=3.21) nor with thrombosis risk (OR=1.41; CI: 0.71-2.8; P=0.33). Antinuclear antibody level was not associated with risk of mortality or severity (risk for mortality: OR=3.8; CI=0.78-18.6; P=0.1; I2: 32.3; severity: OR=1.74; CI=0.96-3.16; P=0.07). Evidence currently available is insufficient for a quantitative analysis of autoantibodies association with long COVID-19. Anti-IFN measurement should be considered in COVID-19 follow-up. In a population-based rational, optimized vaccination strategies should be considered for individuals with anti-IFN antibodies since it could represent a risk for a worse prognosis. High-quality prospective studies for short- and long-term disease effects and autoantibody evaluation are still needed.